Thomas L Harrison
CIK 1247340 · Chrmn/CEO Divers. Agency Serv. · last filed 2026-10-02
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
OMC price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| AGEN | Director | 51,988 | $7.15 | $371.7K | $0 | 10 | 2026-10-02 |
| ACXP | Director | — | $1.06 | — | $0 | 4 | 2026-04-22 |
| AFCG | Director | 24,539 | $3.44 | $84.3K | $95.0K | 6 | 2025-11-24 |
| Zynerba Pharmaceuticals, Inc. (ZYNE) Delisted | Director | 12,500 | $1.30 | $16.2K | $175.0K | 8 | 2018-06-07 |
| SBH | Director | 0 | $19.49 | $0 | -$187.1K | 5 | 2017-12-11 |
| PLx Pharma Inc. (PLXP) Delisted | Director | — | $0.09 | — | $0 | 1 | 2017-04-20 |
| Fifth Street Asset Management Inc. (FSAM) Delisted | Director | 6,000 | — | — | $102.0K | 4 | 2016-03-18 |
| PLx Pharma Inc. (DPRX) Delisted | Director | 18,604 | — | — | $24.0K | 3 | 2016-01-21 |
| EPOCRATES INC (EPOC) Delisted | Director | — | — | — | $0 | 3 | 2013-03-13 |
| Morgans Hotel Group Co. (MHGC) Delisted | Director | 41,269 | — | — | $0 | 5 | 2012-05-21 |
| OMC | Chrmn/CEO Divers. Agency Serv. | 199,149 | $88.50 | $17.62M | -$3.02M | 6 | 2010-03-31 |
Recent Filings · Page 3 of 6
56 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-06-07 | Zynerba Pharmaceuticals, Inc. (ZYNE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-12-11 | SBH | Sell (S) | −6,000 | -$24.3K | EDGAR |
| 2017-12-11 | SBH | Mixed | — | -$15.8K | EDGAR |
| 2017-12-04 | SBH | Mixed | — | -$15.8K | EDGAR |
| 2017-10-03 | Zynerba Pharmaceuticals, Inc. (ZYNE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-07-06 | Zynerba Pharmaceuticals, Inc. (ZYNE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-06-09 | Zynerba Pharmaceuticals, Inc. (ZYNE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-05-08 | SBH | Grant (A) | — | $0 | EDGAR |
| 2017-04-20 | PLx Pharma Inc. (PLXP) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-04-04 | Zynerba Pharmaceuticals, Inc. (ZYNE) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.